Comparison of effects of two treatment schemes in Helicobacter pylori
Grażyna Bała, Grażyna Mierzwa, Mieczysława Czerwionka-Szaflarska, Anna Szaflarska-SzczepanikMed Sci Monit 1999; 5(5): CR885-890 :: ID: 503347
Abstract
The aim of the present work was to compare the efficiency and tolerance of two therapies applied for the treatment of H. pylori infection in children with gastritis and duodenitis and chronic duodenal ulcer disease. 153 test subjects (aged 7-17 years) with gastritis and duodenitis as well as chronic ulcer disease and H.p. infection took part in the study. The children received two different types of therapy.Scheme I (94 children aged 7-12 years): Bismuth citrate (8 mg/kg/day in 4 doses for 6 weeks), Amoxicillin (50 mg/kg/day in 3 doses for 2 weeks), Metronidazole (20 mg/kg/day in 3 doses for 2 weeks). Scheme II (59 children aged 10-17 years, body mass > 35 kg): Pantoprazole (2x40 mg in 2 doses), Clarithromycin (15 mg/kg/day in 2 doses), Metronidazole (20 mg/kg/day in 2 doses) for 7 days. In patients with duodenal ulcer treated according to scheme II, the therapy was continued with 1x40 mg pantoprazole for the following 14 days. Clinical, endoscopic and histological assessment of treatment efficiency was performed. The presence of H.p. infection was determined before and 4-6 weeks after the completion of treatment.
Results: H.p. eradication with the regression of clinical symptoms,macroscopic and histological improvement of mucosa and the healing of duodenal ulcer was obtained in 85% children treated according to scheme I. As far as scheme II is concerned, eradication of H.p. infection together with clinical, macroscopic and histological improvement as well as the healing of ulceration in duodenal bulb was observed in 93% children. Adverse reactions such as headache, nausea, mycosis were recorded only in 2.8% children treated according to scheme I.The comparative analysis performed by our team showed the superiority of scheme II due to its high efficiency in the treatment of duodenal ulcer, large extent of H.p. eradication, good tolerance and short therapy duration.
key words: Helicobacter pylori, children, treatment, pantoprazole,clarithromycin
Keywords: clarithromycin, pantoprazole, treatment, children, Helicobacter pylori
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952